NMRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Portfolio Pulse from
Bronstein, Gewirtz and Grossman, LLC has filed a class action lawsuit against Neumora Therapeutics (NMRA) alleging that the company misrepresented risks and uncertainties in its Phase Three clinical trial program during its September 2023 IPO. The lawsuit claims the company failed to disclose material information about its Navacaprant drug trial, including amended trial criteria and inadequate patient population data.
March 21, 2025 | 11:15 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Class action lawsuit alleges misleading IPO disclosures about clinical trial risks, which could negatively impact investor confidence and stock performance.
The lawsuit directly targets Neumora's IPO representations, suggesting potential financial and reputational damage that could negatively impact stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100